Enovis vs Inogen
ENOV and INGN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENOV and INGN compare
Enovis is the larger company, worth 11 times as much as Inogen ($1.6B against $151M).
Inogen grew revenue faster over the last twelve months (13.7% versus 3.3% for Enovis).
Inogen keeps more of each dollar of sales as profit, with a net margin of −9.3% compared with −22.9% at Enovis.
Inogen scores higher on the StockData Score (12 against 7 for Enovis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENOV | INGN |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $151M |
| Share price | $27.68 | $5.69 |
| Change, 1 year | −11.4% | −19.7% |
| Change, 5 years | −81.7% | −82.8% |
| Beta (5Y) | 1.14 | 1.25 |
| Employees | 7,802 | 314 |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× | 0.4× (better) |
| P/B | 1.1× | 1.0× (better) |
| EV/EBITDA | 3.3× | – |
| P/FCF | 22.9× | – |
| FCF yield | 4.4% (better) | −7.5% |
| Fair value | – | $17.93 |
| Margin of safety | – | 68.3% |
| Growth | ||
| Revenue growth (TTM) | 3.3% | 13.7% (better) |
| Revenue growth, 5Y average | 14.9% (better) | 2.5% |
| Profitability | ||
| Gross margin | 61.3% (better) | 44.1% |
| Operating margin | −20.6% | −11.0% (better) |
| Net margin | −22.9% | −9.3% (better) |
| FCF margin | 3.0% (better) | −3.0% |
| Return on equity | −30.0% | −20.0% (better) |
| Return on invested capital | −12.3% (better) | −49.2% |
| Financial health | ||
| Debt / equity | 0.84 (better) | 0.00 |
| Net debt / EBITDA | 1.43 | – |
| Interest coverage | −14.7× | – |
| Current ratio | 2.15 | 2.96 (better) |
| Altman Z-score | 0.29 | 1.30 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 122% | 72.9% |
| Held by insiders | 2.7% | 3.7% |
| Insider net buying, 12 months | $792K (better) | −$143K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 18.8% | 5.5% |
Go deeper
- ENOV stock overview
- ENOV income statement
- ENOV valuation and score
- INGN stock overview
- INGN income statement
- INGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.